|
Volumn 129, Issue 3, 2015, Pages 467-468
|
High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CHEMOKINE RECEPTOR CCR5;
MARAVIROC;
NATALIZUMAB;
CHEMOKINE RECEPTOR CCR5 ANTAGONIST;
CYCLOHEXANE DERIVATIVE;
TRIAZOLE DERIVATIVE;
B LYMPHOCYTE;
CD4+ T LYMPHOCYTE;
CD8+ T LYMPHOCYTE;
CYTOTOXIC T LYMPHOCYTE;
DRUG SAFETY;
HUMAN;
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME;
IMMUNOHISTOCHEMISTRY;
LETTER;
MULTIPLE SCLEROSIS;
PATHOGENESIS;
PRIORITY JOURNAL;
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;
PROTEIN EXPRESSION;
PROTEIN FUNCTION;
BIOSYNTHESIS;
LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;
METABOLISM;
B-LYMPHOCYTES;
CCR5 RECEPTOR ANTAGONISTS;
CD4-POSITIVE T-LYMPHOCYTES;
CD8-POSITIVE T-LYMPHOCYTES;
CYCLOHEXANES;
HUMANS;
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME;
LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;
MULTIPLE SCLEROSIS;
NATALIZUMAB;
RECEPTORS, CCR5;
TRIAZOLES;
|
EID: 84925493553
PISSN: 00016322
EISSN: 14320533
Source Type: Journal
DOI: 10.1007/s00401-015-1391-6 Document Type: Letter |
Times cited : (18)
|
References (4)
|